Perspectives in Renal Medicine
Kidney International (2004) 66, 1–9; doi:10.1111/j.1523-1755.2004.00701.x
Aldosterone in the development and progression of renal injury
NORMAN K HOLLENBERG
Department of Medicine and Department of Radiology, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts
Correspondence: Norman K. Hollenberg M.D., Ph.D., Brigham & Women's Hospital, 75 Francis Street, Boston, MA 02115. E-mail: djpagecapo@rics.bwh.harvard.edu
Received 16 July 2003; Revised 2 October 2003; Accepted 5 December 2003.
Abstract
Aldosterone in the development and progression of renal injury.
Background
The renin-angiotensin-aldosterone system (RAAS) contributes to hypertension and nephropathy. Until recently, aldosterone either has not been considered or has been considered a relatively minor component of the process—a contribution that could be negated with angiotensin-converting enzyme (ACE) inhibition or angiotensin receptor blockade.
Methods
A Medline search was performed to identify relevant literature describing the role of aldosterone in the pathogenesis of renal dysfunction.
Results
Growing evidence from experimental and clinical studies indicates that increased aldosterone is an independent contributor to small- and medium-sized arterial injury and nephropathy. Excess mineralocorticoid receptor stimulation of local and systemic origin promotes target organ dysfunction, vascular injury, and fibrosis, independent of the effects of other elements of the RAAS. Blockade of the RAAS with ACE inhibition or angiotensin receptor blockade often does not confer optimal protection from the effects of mineralocorticoids on small- and medium-sized blood vessels. Recent preliminary data from clinical studies indicate that aldosterone blockade protects the kidneys, sharply decreases proteinuria, beyond the activities of ACE inhibition or angiotensin receptor blockade and independent of beneficial blood pressure effects, and can protect patients from vascular injury associated with diabetes mellitus and hypertension.
Conclusion
Aldosterone blockade with the selective aldosterone blocker eplerenone, in combination with other RAAS inhibitors, is probably renoprotective and should be considered as a component of the treatment regimens of diabetic and hypertensive patients at risk for renal or cardiovascular disease expression. A high priority should be placed on developing the randomized, controlled trials required to establish that role.
Keywords:
blood vessels, diabetes, eplerenone, hypertension, kidney, renoprotection, renal vasculature
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection
Nature Reviews Drug Discovery Review (01 Nov 2008)
Nature Clinical Practice Nephrology Review (01 Jan 2007)
Nature Clinical Practice Nephrology Review (01 Jan 2007)
NEWS AND VIEWS
Pharmacotherapy Cardiovascular effects of aldosterone blockade in CKD
Nature Reviews Cardiology News and Views (01 Nov 2009)
RESEARCH
Kidney International Original Article


